Cappella, a medical device company developing solutions for the treatment of coronary bifurcation disease, has appointed David Blossom as vice president of commercial operations.
Mr Blossom is a sales and marketing executive with 20 years of medical device experience, most recently at Covidien/Aspect Medical Systems and previously at Boston Scientific.
Art Rosenthal, CEO of Cappella, said: “David provides the exceptional skills and depth of experience needed to lead the commercial effort as we continue to transition from an R&D to a commercial enterprise. David’s record of success in market development and commercialization of innovative medical devices will have a significant impact as we implement our commercialization plans of the Sideguard Coronary Sidebranch Stent.
Cappella’s initial product, the Sideguard Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a solution that focuses on treating the sidebranch of diseased coronary arteries first, allowing the preferred stent of choice for the main vessel.